AZNLondon Stock Exchange
AstraZeneca
The verified shareholder board for AstraZeneca. Discuss AstraZeneca (AZN) with other verified holders — real people, considered discussion, and a collective voice the company has a reason to answer.
Where the discussion stands
AstraZeneca has secured EU approval of Enhertu for HER2-positive solid tumours, alongside an EU recommendation for approval of Datroway in triple-negative breast cancer. Both developments relate to the company's oncology portfolio and its collaborations in antibody-drug conjugates. For shareholders, the questions that now matter most are how broadly these indications expand the addressable patient populations and what they could mean for the trajectory of AstraZeneca's cancer franchise. The next step on Datroway will be whether the recommendation converts into formal EU authorisation, and how quickly each treatment reaches patients across member states.
What shareholders are weighing
- AstraZeneca has received EU approval for Enhertu in HER2-positive solid tumours and a positive CHMP recommendation for Datroway in triple-negative breast cancer — how significant do shareholders consider these regulatory milestones for AZN's oncology pipeline and near-term revenue outlook?
Join the discussion
The Shareholders Board is a community of verified shareholders — real people, no bots, no anonymous accounts. Reading and joining the conversation about AstraZeneca is for members.
Nothing on this page is investment advice or a recommendation to buy or sell any security. It is a place to discuss the companies you own with other verified owners.